Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping

The crystal structure of human cystatin C, a protein with amyloidogenic properties and a potent inhibitor of cysteine proteases, reveals how the protein refolds to produce very tight two-fold symmetric dimers while retaining the secondary structure of the monomeric form. The dimerization occurs through three-dimensional domain swapping, a mechanism for forming oligomeric proteins. The reconstituted monomer-like domains are similar to chicken cystatin except for one inhibitory loop that unfolds to form the 'open interface' of the dimer. The structure explains the tendency of human cystatin C to dimerize and suggests a mechanism for its aggregation in the brain arteries of elderly people with amyloid angiopathy. A more severe 'conformational disease' is associated with the L68Q mutant of human cystatin C, which causes massive amyloidosis, cerebral hemorrhage and death in young adults. The structure of the three-dimensional domain-swapped dimers shows how the L68Q mutation destabilizes the monomers and makes the partially unfolded intermediate less unstable. Higher aggregates may arise through the three-dimensional domain-swapping mechanism occurring in an open-ended fashion in which partially unfolded molecules are linked into infinite chains.

[1]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[2]  M. Skinner,et al.  Characterization of the Amyloid Fibril as a Cross-β Protein∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[3]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[4]  M. Abrahamson,et al.  Increased body temperature accelerates aggregation of the Leu-68-->Gln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C R Kissinger,et al.  Rapid automated molecular replacement by evolutionary search. , 1999, Acta crystallographica. Section D, Biological crystallography.

[6]  J. Kos,et al.  The structures of native phosphorylated chicken cystatin and of a recombinant unphosphorylated variant in solution. , 1993, Journal of molecular biology.

[7]  John J. Barker,et al.  Engineering an intertwined form of CD2 for stability and assembly , 1998, Nature Structural Biology.

[8]  R. Gentz,et al.  Cystatin F Is a Glycosylated Human Low Molecular Weight Cysteine Proteinase Inhibitor* , 1998, The Journal of Biological Chemistry.

[9]  W. Bode,et al.  cystatins: protein inhibitors of cysteine proteinases , 2001 .

[10]  J. Waltho,et al.  The three-dimensional solution structure of human stefin A. , 1995, Journal of molecular biology.

[11]  I. Ekiel,et al.  Two stable unfolding intermediates of the disease-causing L68Q variant of human cystatin C. , 1998, Biochemistry.

[12]  D Eisenberg,et al.  The crystal structure of a 3D domain-swapped dimer of RNase A at a 2.1-A resolution. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Huber,et al.  Conformational variability of chicken cystatin. Comparison of structures determined by X-ray diffraction and NMR spectroscopy. , 1993, Journal of molecular biology.

[14]  I. Ekiel,et al.  Folding-related Dimerization of Human Cystatin C (*) , 1996, The Journal of Biological Chemistry.

[15]  N. Rawlings,et al.  Cloning, Isolation, and Characterization of Mammalian Legumain, an Asparaginyl Endopeptidase* , 1997, The Journal of Biological Chemistry.

[16]  W. Bode,et al.  The 2.0 A X‐ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. , 1988, The EMBO journal.

[17]  Alan J. Barrett,et al.  An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation , 1998, Nature.

[18]  D Eisenberg,et al.  Oligomer formation by 3D domain swapping: a model for protein assembly and misassembly. , 1997, Advances in protein chemistry.

[19]  A. Grubb Cystatin C-Properties and use as diagnostic marker , 2001, Advances in Clinical Chemistry.

[20]  M. Jaskólski,et al.  Expression of a selenomethionyl derivative and preliminary crystallographic studies of human cystatin C , 1999, Acta crystallographica. Section D, Biological crystallography.

[21]  D. Eisenberg,et al.  Domain swapping: entangling alliances between proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Huber,et al.  The refined 2.4 A X‐ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. , 1990, The EMBO journal.

[23]  A. Barrett,et al.  Inhibition of Mammalian Legumain by Some Cystatins Is Due to a Novel Second Reactive Site* , 1999, The Journal of Biological Chemistry.

[24]  D Eisenberg,et al.  3D domain swapping: A mechanism for oligomer assembly , 1995, Protein science : a publication of the Protein Society.

[25]  K. Gehring,et al.  NMR structural studies of human cystatin C dimers and monomers. , 1997, Journal of molecular biology.

[26]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.